NASDAQ · AZN
Healthcare · Drug Manufacturers - General
$162.70
Down-$0.57 (-0.35%)
Updated Aug 31, 2026, 9:34 PM
SID Score
7.1/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AZN closed at $162.70 after 20 trading sessions, up 2.99% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $163.52 | $163.54 | $161.18 | $162.70 | 2.88M |
| Aug 27, 2026 | $165.27 | $165.58 | $163.98 | $164.52 | 2.5M |
| Aug 26, 2026 | $167.46 | $167.89 | $165.17 | $166.27 | 2.68M |
| Aug 25, 2026 | $167.08 | $170.18 | $166.78 | $169.66 | 3.45M |
| Aug 24, 2026 | $164.57 | $167.08 | $163.97 | $166.71 | 2.78M |
| Aug 21, 2026 | $164.04 | $167.25 | $163.96 | $165.98 | 3.18M |
| Aug 20, 2026 | $163.40 | $165.57 | $161.475 | $164.49 | 5.09M |
| Aug 19, 2026 | $162.13 | $165.91 | $162.00 | $164.95 | 3.82M |
| Aug 18, 2026 | $159.12 | $160.64 | $158.98 | $160.10 | 3M |
| Aug 17, 2026 | $156.30 | $157.26 | $155.78 | $156.89 | 3.36M |
| Aug 14, 2026 | $155.50 | $156.46 | $154.53 | $156.45 | 3.7M |
| Aug 13, 2026 | $157.85 | $158.44 | $156.97 | $157.24 | 3.6M |
| Aug 12, 2026 | $157.68 | $159.0226 | $157.12 | $158.50 | 4.14M |
| Aug 11, 2026 | $162.06 | $162.26 | $158.61 | $158.75 | 2.75M |
| Aug 10, 2026 | $160.59 | $162.72 | $160.25 | $161.91 | 3.75M |
| Aug 7, 2026 | $162.14 | $162.18 | $160.00 | $161.42 | 3.72M |
| Aug 6, 2026 | $162.62 | $162.93 | $159.75 | $161.07 | 2.35M |
| Aug 5, 2026 | $163.79 | $164.45 | $160.72 | $161.50 | 7M |
| Aug 4, 2026 | $157.95 | $158.56 | $155.32 | $155.62 | 8.1M |
| Aug 3, 2026 | $157.165 | $159.715 | $153.4134 | $157.97 | 16.31M |
The latest Smart Investors Daily articles mentioning AZN.
AZN research
Company profile and research snapshot.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
Generated Aug 31, 2026, 7:02 PM
AstraZeneca shares declined 0.16% today following negative clinical trial results that have spooked investors in the broader biotech sector. The company's cardiomyopathy program failed to deliver, raising concerns about its pipeline efficacy and potentially signaling headwinds for similar programs across the industry.
Bottom line: AstraZeneca's failed cardiomyopathy trial is a meaningful setback, but the market's muted reaction suggests investors view it as a manageable blow rather than a pipeline crisis. Investors should monitor whether management adjusts guidance and how the company reallocates R&D resources, while watching for any contagion effects in similar cardiovascular programs across the sector.
Yahoo · Aug 31, 2026
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.
Yahoo · Aug 29, 2026
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
Yahoo · Aug 28, 2026
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
Yahoo · Aug 28, 2026
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC shares currently trade at $162.70, reflecting a decline of 5.04% over the past month and a steeper 12.37% pullback over the trailing three-month period, per SID market data. Despite this near-term weakness, the stock has delivered a robust 103.25% gain over the past twelve months, underscoring significant longer-term momentum. From a technical perspective, AZN trades below its 50-day moving average of $170.85 but remains above its 200-day moving average of $158.50, according to Massive/Polygon data, suggesting the stock sits in a short-term corrective phase within a broader uptrend. The 14-day RSI reads 51.5, indicating neutral momentum with neither overbought nor oversold conditions. AZN's beta of 0.168 reflects exceptionally low volatility relative to the broader market, consistent with its defensive healthcare sector positioning. Average daily trading volume stands at approximately 5.47 million shares, supporting adequate liquidity for institutional participants.
AstraZeneca PLC carries a market capitalization of approximately $279.9 billion, positioning it among the largest global pharmaceutical companies. The stock trades at a price-to-earnings ratio of 33.06, per SID market data, which represents a premium relative to the broader healthcare sector. The PEG ratio stands at 4.53, according to SEC filings, suggesting that the current valuation meaningfully exceeds what projected earnings growth alone would justify. AZN's price-to-book ratio of 6.24 further reflects elevated valuation multiples, indicative of the market pricing in substantial intangible asset value including its oncology and rare disease pipeline. The company offers a modest dividend yield of 1.56%, providing limited income return relative to its premium valuation. These metrics collectively indicate that AstraZeneca is priced at a significant premium to fundamental benchmarks, with the valuation embedding expectations for sustained revenue growth from its clinical pipeline and commercial portfolio expansion.
AstraZeneca PLC registers a smart money score of 62 out of 100 with a neutral overall signal, per SID market data. The institutional component scores a perfect 25 out of 25, reflecting strong and sustained institutional ownership and positioning in the stock. In contrast, the insider trading component scores 12.5 out of 25, though recent insider activity has been exclusively bullish — SEC Form 4 filings show three insider purchases and zero insider sales over the past 90 days. This buying pattern suggests that company executives view current price levels as attractive following the recent pullback. The dark pool activity score registers at 12.4 out of 25, indicating moderate but unremarkable off-exchange trading activity. Congressional trading activity scores 12 out of 25, per 13F institutional filings, showing neither significant accumulation nor distribution by political officeholders. The divergence between maximum institutional conviction and more moderate scores across other smart money categories produces the composite neutral reading.
AstraZeneca PLC has demonstrated a strong pattern of outperforming consensus expectations in recent quarters. In its most recently reported quarter, the company posted earnings of $2.63 per share against an analyst estimate of $1.52, delivering a positive surprise of $1.11, according to company earnings reports. The prior quarter similarly exceeded expectations, with actual earnings of $2.58 versus the $1.53 consensus estimate, representing a $1.05 beat. These consecutive substantial beats reflect the company's accelerating revenue trajectory across its oncology and biopharmaceutical franchises. Looking ahead, per analyst estimates, the next upcoming quarter carries a consensus earnings estimate of $1.75, while the following quarter projects $1.44. The sequential decline in forward estimates may partially reflect seasonal prescribing patterns and the timing of regulatory milestones. Given the magnitude of recent positive surprises, the forward estimates could prove conservative if AstraZeneca maintains its current commercial and pipeline execution trajectory.
Wall Street analyst coverage of AstraZeneca PLC reveals a divided consensus, per SID consensus data. In the most recent rating action dated July 13, 2026, Berenberg Bank reiterated a Buy rating on AZN, reinforcing a constructive outlook on the company's pipeline and commercial execution. Jefferies has also maintained a Buy rating on two separate occasions, issuing reiterations on both June 26 and June 9, 2026, according to Wall Street analyst reports. Conversely, Deutsche Bank has taken a contrarian stance, reiterating a Sell rating twice during the same period — on June 26 and June 11, 2026. This split reflects the ongoing debate around AstraZeneca's premium valuation at a 33.06 P/E multiple versus its strong earnings momentum, with bulls emphasizing the oncology portfolio growth and bears pointing to stretched multiples. The concentration of recent activity from just three firms suggests broader coverage may be awaiting upcoming catalysts before adjusting positions.
The latest Smart Investors Daily articles mentioning AZN.
